

DAFTAR PUSTAKA

- Adams, L. A. *et al.* (2005) 'The natural history of nonalcoholic fatty liver disease: A population-based cohort study', *Gastroenterology*, 129(1), pp. 113–121. doi: 10.1053/j.gastro.2005.04.014.
- Adiwinata, R. *et al.* (2017) 'Tatalaksana Terkini Perlemakan Hati Non Alkoholik', *Jurnal Penyakit Dalam Indonesia*, 2(1), p. 53. doi: 10.7454/jpdi.v2i1.65.
- AlSaffar, R. M. *et al.* (2022) 'D-limonene (5 (one-methyl-four-[1-methylethenyl]) cyclohexane) diminishes CCl₄-induced cardiac toxicity by alleviating oxidative stress, inflammatory and cardiac markers', *Redox Report*, 27(1), pp. 92–99. doi: 10.1080/13510002.2022.2062947.
- Amor, A. J. (2019) 'Dyslipidemia in nonalcoholic fatty liver disease', (July 2021). *Curr Opin Endocrinol Diabetes Obes* 2019, 26:103–108 doi: 10.1097/MED.0000000000000464.
- Aragno, M. *et al.* (2009) 'SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats', *Free Radical Biology and Medicine*, 47(7), pp. 1067–1074. doi: 10.1016/j.freeradbiomed.2009.07.016.
- Bharathi, P. and Pennarsi, M. (2016) 'Production of lipids from municipal sewage sludge by two stage extraction process', *ASEAN Journal of Chemical Engineering*, 16(1), pp. 38–44. doi: 10.22146/ajche.49672.
- Bhat, M. A. *et al.* (2019) 'Synthesis and antihepatotoxic activity of dihydropyrimidinone derivatives linked with 1,4-benzodioxane', *Drug Design, Development and Therapy*, 13, pp. 2393–2404. doi: 10.2147/DDDT.S198865.
- Bommer, G. T. and MacDougald, O. A. (2011) 'Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus', *Cell Metabolism*, 13(3), pp. 241–247. doi: 10.1016/j.cmet.2011.02.004.
- Brunt, E. M. *et al.* (2011) 'Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings', *Hepatology*, 53(3), pp. 810–820. doi: 10.1002/hep.24127.
- Brunt, E. M. and Tiniakos, D. G. (2010) 'Histopathology of nonalcoholic fatty liver disease', *World Journal of Gastroenterology*, 16(42), pp. 5286–5296. doi: 10.3748/wjg.v16.i42.5286.
- Buzzetti, E., Pinzani, M. and Tsochatzis, E. A. (2016) 'The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)', *Metabolism*, pp. 1–11. doi: 10.1016/j.metabol.2015.12.012.
- Cahyono, S. B. *et al.* (2013) 'Ultrasound-diagnosed non-alcoholic fatty liver disease among medical check up patients', *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy*, 14(3), pp. 145–149.
- Cao, X. *et al.* (2022) 'The Effect of MUFA-Rich Food on Lipid Profile':
- Carreres, L. *et al.* (2021) 'Modeling diet-induced nafld and nash in rats: A comprehensive review', *Biomedicines*, 9(4). doi: 10.3390/biomedicines9040378.
- Caturano, A. *et al.* (2021) 'Non-alcoholic fatty liver disease: From pathogenesis to clinical impact', *Processes*, 9(1), pp. 1–18. doi: 10.3390/pr9010135.

- Cha, S. H. *et al.* (2020) 'Diphlorethohydroxycarmalol attenuates palmitate-induced hepatic lipogenesis and inflammation', *Marine Drugs*, 18(9). doi: 10.3390/md18090475.
- Chalasani, N. *et al.* (2018) 'The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases', *Hepatology*, 67(1), pp. 328–357. doi: 10.1002/hep.29367.
- Chatrath, H., Vuppalandhi, R. and Chalasani, N. (2012) 'Dyslipidemia in patients with nonalcoholic fatty liver disease', *Seminars in Liver Disease*, 32(1), pp. 22–29. doi: 10.1055/s-0032-1306423.
- Chaturvedi, P. and Kwape, T. E. (2015) 'Attenuation of Diabetic Conditions by *Sida rhombifolia* in Moderately Diabetic Rats and Inability to Produce Similar Effects in Severely Diabetic in Rats', *Journal of Pharmacopuncture*, 18(4), pp. 12–19. doi: 10.3831/kpi.2015.18.032.
- Chaves, O. S. *et al.* (2013) 'Secondary metabolites from *Sida rhombifolia* L. (Malvaceae) and the vasorelaxant activity of cryptolepinone', *Molecules*, 18(3), pp. 2769–2777. doi: 10.3390/molecules18032769.
- Chaves, O. S. *et al.* (2017) 'Alkaloids and phenolic compounds from *Sida rhombifolia* L. (Malvaceae) and vasorelaxant activity of two indoquinoline alkaloids', *Molecules*, 22(1). doi: 10.3390/molecules22010094.
- Cominguez, D. C. *et al.* (2022) 'Clitorin ameliorates western diet-induced hepatic steatosis by regulating lipogenesis and fatty acid oxidation in vivo and in vitro', *Scientific Reports*, 12(1), pp. 1–14. doi: 10.1038/s41598-022-07937-3.
- Corton, J. C. (2020) *EPA Public Access*. doi: 10.1016/j.comtox.2019.01.007.Submit.
- Cristina da Costa Araldi, I. *et al.* (2021) 'Preclinical safety assessment of the crude extract from *Sida rhombifolia* L. aerial parts in experimental models of acute and repeated-dose 28 days toxicity in rats', *Regulatory Toxicology and Pharmacology*, 124(February). doi: 10.1016/j.yrtph.2021.104974.
- Cunningham, R. P. and Porat-Shliom, N. (2021) 'Liver Zonation – Revisiting Old Questions With New Technologies', *Frontiers in Physiology*, 12(September), pp. 1–17. doi: 10.3389/fphys.2021.732929.
- Devkar, R. *et al.* (2009a) 'Assessment of lipid lowering effect of *Sida rhombifolia* methanolic extract in experimentally induced hyperlipidemia', *Journal of Young Pharmacists*, 1(3), p. 233. doi: 10.4103/0975-1483.57070.
- Devkar, R. *et al.* (2009b) 'Assessment of lipid lowering effect of *Sida rhombifolia* methanolic extract in experimentally induced hyperlipidemia', *Journal of Young Pharmacists*, 1(3), p. 233. doi: 10.4103/0975-1483.57070.
- Dhalwal, K. *et al.* (2010) 'Hypoglycemic and hypolipidemic effect of *Sida rhombifolia* ssp. *retusa* in diabetic induced animals', *International Journal of Phytomedicine*, 2(2), pp. 160–165. doi: 10.5138/ijpm.2010.0975.0185.02025.
- DiNicolantonio, J. J. and O'Keefe, J. H. (2018) 'Effects of dietary fats on blood lipids: A review of direct comparison trials', *Open Heart*, 5(2), pp. 1–5. doi: 10.1136/openhrt-2018-000871.

- Dowman, J. K., Tomlinson, J. W. and Newsome, P. N. (2009) 'Pathogenesis of non-alcoholic fatty liver disease', *Qjm*, 103(2), pp. 71–83. doi: 10.1093/qjmed/hcp158.
- Dowman, J. K., Tomlinson, J. W. and Newsome, P. N. (2011) 'Systematic review: The diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis', *Alimentary Pharmacology and Therapeutics*, 33(5), pp. 525–540. doi: 10.1111/j.1365-2036.2010.04556.x.
- Duseja, A. and Chalasani, N. (2013) 'Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD)', *Hepatology International*, 7(2013), pp. S755–S764. doi: 10.1007/s12072-013-9480-x.
- Esler, W. P. and Bence, K. K. (2019) 'Metabolic Targets in Nonalcoholic Fatty Liver Disease', *Cmgh*, 8(2), pp. 247–267. doi: 10.1016/j.jcmgh.2019.04.007.
- Ferré, P. and Foufelle, F. (2007) 'SREBP-1c transcription factor and lipid homeostasis: Clinical perspective', *Hormone Research*, 68(2), pp. 72–82. doi: 10.1159/000100426.
- Ferré, P. and Foufelle, F. (2010) 'Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c', *Diabetes, Obesity and Metabolism*, 12(SUPPL. 2), pp. 83–92. doi: 10.1111/j.1463-1326.2010.01275.x.
- Ferro, D. *et al.* (2020) 'New insights into the pathogenesis of non-alcoholic fatty liver disease: Gut-derived lipopolysaccharides and oxidative stress', *Nutrients*, 12(9), pp. 1–14. doi: 10.3390/nu12092762.
- Ferro, D. M. *et al.* (2019) 'Integrated extraction approach to increase the recovery of antioxidant compounds from Sida rhombifolia leaves', *Journal of Supercritical Fluids*, 149, pp. 10–19. doi: 10.1016/j.supflu.2019.03.013.
- Ganjooei, N. A. *et al.* (2021) 'The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients', *Frontiers in Cardiovascular Medicine*, 8(May), pp. 1–11. doi: 10.3389/fcvm.2021.682352.
- Gautam, M. K. and Goel, R. K. (2012) 'Exploration of preliminary phytochemical studies of leaves of *Murraya paniculata* (L .)', *international Journal of Pharmacy & Life Sciences*, 3(8), pp. 1871–1874.
- Ha, J. H. *et al.* (2016) 'AMPK and SREBP-1c mediate the anti-adipogenic effect of hydroxyisovalerylshikonin', *International Journal of Molecular Medicine*, 37(3), pp. 816–824. doi: 10.3892/ijmm.2016.2484.
- Haas, J. T., Francque, S. and Staels, B. (2016) 'Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease', *Annual Review of Physiology*, 78(March), pp. 181–205. doi: 10.1146/annurev-physiol-021115-105331.
- Halegoua-De Marzio, D. L. and Fenkel, J. M. (2014) 'Concepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease', *Advances in Hepatology*, 2014, pp. 1–7. doi: 10.1155/2014/357965.
- Hanifa, N. I. and Widyaningsih, W. (2020) 'Efek Hepatoprotektif Ekstrak Etanol Daun Sidaguri (Sida rhombifolia L .) terhadap Aktivitas Alkalin Fosfatase Serum Tikus yang diinduksi Karbon Tetraklorida', 8(2), pp. 45–52.
- Hartanti, L. *et al.* (2019) 'Influence of extraction methods of bay leaves (*Syzygium polyanthum*) on antioxidant and HMG-CoA Reductase inhibitory activity', *Heliyon*, 5(4), p. e01485. doi: 10.1016/j.heliyon.2019.e01485.

- Hashimoto, E., Taniai, M. and Tokushige, K. (2013) 'Characteristics and diagnosis of NAFLD/NASH', *Journal of Gastroenterology and Hepatology (Australia)*, 28(S4), pp. 64–70. doi: 10.1111/jgh.12271.
- Van Herck, M. A., Vonghia, L. and Francque, S. M. (2017) 'Animal models of nonalcoholic fatty liver disease—a starter's guide', *Nutrients*, 9(10), pp. 1–13. doi: 10.3390/nu9101072.
- Horton, J. D. (2002) 'Sterol regulatory element-binding proteins: Transcriptional activators of lipid synthesis', *Biochemical Society Transactions*, 30(6), pp. 1091–1095. doi: 10.1042/BST0301091.
- Ikhtiarini, A. N. *et al.* (2021) 'Optimization of ultrasound-assisted extraction and the antioxidant activities of Sidaguri (*Sida rhombifolia*)', *Journal of Applied Pharmaceutical Science*, 11(8), pp. 70–76. doi: 10.7324/JAPS.2021.110810.
- Illesca, P. *et al.* (2019) 'Hydroxytyrosol supplementation ameliorates the metabolic disturbances in white adipose tissue from mice fed a high-fat diet through recovery of transcription factors Nrf2, SREBP-1c, PPAR- γ and NF- κ B', *Biomedicine and Pharmacotherapy*, 109(September 2018), pp. 2472–2481. doi: 10.1016/j.biopha.2018.11.120.
- Imanuel Setiawan, S. *et al.* (2021) 'Pilihan tatalaksana penyakit perlemakan hati non-alkohol (non-alkoholic fatty liver disease/ nafld)', *Cermin Dunia Kedokteran*, 48(3), pp. 173–175. Available at: <http://www.cdkjournal.com/index.php/CDK/article/view/1336>.
- Iqbal, U. *et al.* (2019) 'The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease', *Medicines*, 6(1), p. 41. doi: 10.3390/medicines6010041.
- Irham, L. M. and Widyaningsih, W. (2017) 'Aktifitas hepatoprotektif ekstrak etanol daun sidaguri (*sida rhombifolia* l.) dilihat dari rasio berat hepar, nilai sgpt-sgot, dan histopatologi hepar pada tikus sprague dawley yang diinduksi ccl4', *Media Farmasi: Jurnal Ilmu Farmasi*, 14(1), p. 61. doi: 10.12928/mf.v14i1.9826.
- Jarvis, H. *et al.* (2020) 'Metabolic risk factors and incident advanced liver disease in non-alkoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies', *PLoS Medicine*, 17(4). doi: 10.1371/JOURNAL.PMED.1003100.
- Jiang, Z. G. *et al.* (2013) 'Lipoprotein metabolism in nonalcoholic fatty liver disease', (January). doi: 10.7555/JBR.27.20120077.
- Ju, U. Il *et al.* (2020) 'Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment', *Cell Death and Disease*, 11(4). doi: 10.1038/s41419-020-2472-6.
- Kim, C. W. *et al.* (2017) 'Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation', *Cell Metabolism*, 26(2), p. 394–406.e6. doi: 10.1016/j.cmet.2017.07.009.
- Kim, J. K. *et al.* (2014) 'Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice', *Experimental and Molecular Medicine*, 46(12). doi: 10.1038/emmm.2014.90.

- Kim, S. G. and Lee, W. H. (2010) 'AMPK-dependent metabolic regulation by PPAR agonists', *PPAR Research*, 2010. doi: 10.1155/2010/549101.
- Kubota, N. *et al.* (2013) 'A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice', *Clinical and Experimental Pharmacology and Physiology*, 40(7), pp. 422–430. doi: 10.1111/1440-1681.12102.
- Kucera, O. and Cervinkova, Z. (2014) 'Experimental models of non-alcoholic fatty liver disease in rats', *World Journal of Gastroenterology*, 20(26), pp. 8364–8376. doi: 10.3748/wjg.v20.i26.8364.
- Li, C. *et al.* (2015) 'Dietary n-3 highly unsaturated fatty acids affect the biological and serum biochemical parameters, tissue fatty acid profile, antioxidation status and expression of lipid-metabolism-related genes in grass carp, *Ctenopharyngodon idellus*', *Aquaculture Nutrition*, 21(3), pp. 373–383. doi: 10.1111/anu.12169.
- Li, R. *et al.* (2021) '4-OI Attenuates Carbon Tetrachloride-Induced Hepatic Injury via Regulating Oxidative Stress and the Inflammatory Response', *Frontiers in Pharmacology*, 12(May), pp. 1–13. doi: 10.3389/fphar.2021.651444.
- Li, Y. *et al.* (2016) 'Berberine alleviates olanzapine-induced adipogenesis via the AMPK α -SREBP pathway in 3T3-L1 cells', *International Journal of Molecular Sciences*, 17(11). doi: 10.3390/ijms17111865.
- Lima, M. L. R. P. *et al.* (2016) 'A novel wistar rat model of obesity-related nonalcoholic fatty liver disease induced by sucrose-rich diet', *Journal of Diabetes Research*, 2016. doi: 10.1155/2016/9127076.
- Liu, Y. *et al.* (2020) 'Berberine suppresses colon cancer cell proliferation by inhibiting the SCAP/SREBP-1 signaling pathway-mediated lipogenesis', *Biochemical Pharmacology*, 174(September 2019). doi: 10.1016/j.bcp.2019.113776.
- Lu, F. Bin *et al.* (2020) 'Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis', *Journal of Gastroenterology and Hepatology (Australia)*, 35(12), pp. 2041–2050. doi: 10.1111/jgh.15156.
- Mah, S. H., Teh, S. S. and Ee, G. C. L. (2017) 'Anti-inflammatory, anti-cholinergic and cytotoxic effects of *Sida Rhombifolia*', *Pharmaceutical Biology*, 55(1), pp. 920–928. doi: 10.1080/13880209.2017.1285322.
- Mahmoodzadeh, Y., Mazani, M. and Rezagholizadeh, L. (2017) 'Hepatoprotective Effect of Methanolic Tanacetum Parthenium Extract on CCl₄-Induced Liver Damage in Rats', *Toxicology Reports*. doi: 10.1016/j.toxrep.2017.08.003.
- Marchesini, G. *et al.* (2016) 'EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease', *Journal of Hepatology*, 64(6), pp. 1388–1402. doi: 10.1016/j.jhep.2015.11.004.
- Maria Susanti, C. *et al.* (2014) 'Pengaruh Jumlah Pelarut Etanol Dan Suhu Fraksinasi Terhadap Karakteristik Lemak Kakao Hasil Ekstraksi Non Alkalized Cocoa Powder', *Jurnal Teknologi Industri dan Hasil Pertanian*, 19(2), pp. 307–319.
- Martin, A. *et al.* (2022) 'Management of Dyslipidemia in Patients with Non -

- Alcoholic Fatty Liver Disease', *Current Atherosclerosis Reports*, pp. 533–546. doi: 10.1007/s11883-022-01028-4.
- Moslehi, A. and Hamidi-Zad, Z. (2018) 'Role of SREBPs in liver diseases: A mini-review', *Journal of Clinical and Translational Hepatology*, 6(3), pp. 332–338. doi: 10.14218/JCTH.2017.00061.
- Neuschwander-Tetri, B. A. and Caldwell, S. H. (2003) 'Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference', *Hepatology*, 37(5), pp. 1202–1219. doi: 10.1053/jhep.2003.50193.
- Nevzorova, Y. A. *et al.* (2020) 'Animal models for liver disease – A practical approach for translational research', *Journal of Hepatology*, 73(2), pp. 423–440. doi: 10.1016/j.jhep.2020.04.011.
- Pai, R. K. (2019) 'NAFLD Histology: a Critical Review and Comparison of Scoring Systems', *Current Hepatology Reports*, 18(4), pp. 473–481. doi: 10.1007/s11901-019-00500-1.
- Parthasarathy, G., Revelo, X. and Malhi, H. (2020) 'Pathogenesis of Nonalcoholic Steatohepatitis: An Overview', *Hepatology Communications*, 4(4), pp. 478–492. doi: 10.1002/hep4.1479.
- Petta, S. *et al.* (2016) 'Pathophysiology of Non Alcoholic Fatty Liver Disease', (December). doi: 10.3390/ijms17122082.
- Pettinelli, P., Obregón, A. M. and Videla, L. A. (2011) 'Molecular mechanisms of steatosis in nonalcoholic fatty liver disease', *Nutricion Hospitalaria*, 26(3), pp. 441–450. doi: 10.3305/nh.2011.26.3.5119.
- Rahmania, S., Sulistiyani, S. and Lelono, A. A. (2017) 'Identification of HMG-CoA Reductase Inhibitor Active Compound in Medicinal Forest Plants', *Jurnal Kefarmasian Indonesia*, 7(2), pp. 95–104. doi: 10.22435/jki.v7i2.6279.95-104.
- Ramadoss, S. *et al.* (2019) 'Research Journal of Pharmaceutical , Biological and Chemical Sciences Evaluation of Hepato-Protective Activity in the Ethanolic Extract of Sida rhombifolia Linn . against Paracetamol - Induced Hepatic Injury in Albino Rats', 3(1), pp. 497–502.
- Rastogi, A. *et al.* (2017) 'Non-alcoholic fatty liver disease – histological scoring systems: a large cohort single-center, evaluation study', *Apmis*, 125(11), pp. 962–973. doi: 10.1111/apm.12742.
- Rinella, M. E. (2015) 'Nonalcoholic fatty liver disease a systematic review', *JAMA - Journal of the American Medical Association*, 313(22), pp. 2263–2273. doi: 10.1001/jama.2015.5370.
- Rodríguez-Correa, E. *et al.* (2020) 'Biochemical and nutritional overview of diet-induced metabolic syndrome models in rats: what is the best choice?', *Nutrition and Diabetes*, 10(1). doi: 10.1038/s41387-020-0127-4.
- Saleh Al-Maamari, J. N. *et al.* (2021) 'The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice', *Journal of Basic and Clinical Physiology and Pharmacology*, 32(4), pp. 637–644. doi: 10.1515/jbcpp-2020-0423.
- Sameer, A. S., Aziz, R. and Hamid, S. (2015) 'Association of Lipid Profile and Liver Enzymes Among Non- Alcoholic Fatty Liver Disease Patients Attending a Tertiary Care Research Article Association of Lipid Profile and

- Liver Enzymes Among Non-Alcoholic Fatty Liver', (August 2018).
- Sheng, D. *et al.* (2019) 'BabaoDan attenuates high - fat diet - induced non - alcoholic fatty liver disease via activation of AMPK signaling', *Cell & Bioscience*, pp. 1–10. doi: 10.1186/s13578-019-0339-2.
- Shimano, H. and Sato, R. (2017a) 'SREBP-regulated lipid metabolism: Convergent physiology-divergent pathophysiology', *Nature Reviews Endocrinology*, 13(12), pp. 710–730. doi: 10.1038/nrendo.2017.91.
- Shimano, H. and Sato, R. (2017b) 'SREBP-regulated lipid metabolism: Convergent physiology-divergent pathophysiology', *Nature Reviews Endocrinology*, 13(12), pp. 710–730. doi: 10.1038/nrendo.2017.91.
- Siddiqui, R. A. *et al.* (2015) 'Comparative study of the modulation of fructose/sucrose-induced hepatic steatosis by mixed lipid formulations varying in unsaturated fatty acid content', *Nutrition and Metabolism*, 12(1), pp. 1–14. doi: 10.1186/s12986-015-0038-x.
- Silalahi, M. (2020) 'Pemanfaatan dan Bioaktivitas Sidaguri (Sida rhombifolia)', *Florea: Jurnal Biologi dan Pembelajarannya*, 7(1), p. 22. doi: 10.25273/florea.v7i1.5780.
- Takahashi, Y. and Fukusato, T. (2014) 'Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis', *World Journal of Gastroenterology*, 20(42), pp. 15539–15548. doi: 10.3748/wjg.v20.i42.15539.
- Thounaojam, M. *et al.* (2009) 'Dysregulation of lipid and cholesterol metabolism in high fat diet fed hyperlipidemic rats: Protective effect of Sida rhomboidea. roxb leaf extract', *Journal of Health Science*, 55(3), pp. 413–420. doi: 10.1248/jhs.55.413.
- Thounaojam, M. C., Jadeja, R. N., Ansarullah, *et al.* (2011) 'Cardioprotective effect of Sida rhomboidea. Roxb extract against isoproterenol induced myocardial necrosis in rats', *Experimental and Toxicologic Pathology*, 63(4), pp. 351–356. doi: 10.1016/j.etp.2010.02.010.
- Thounaojam, M. C., Jadeja, R. N., Ramani, U. V., *et al.* (2011) 'Sida rhomboidea. Roxb leaf extract down-regulates expression of PPAR γ 2 and leptin genes in high fat diet fed C57BL/6J mice and retards in vitro 3T3L1 pre-adipocyte differentiation', *International Journal of Molecular Sciences*, 12(7), pp. 4661–4677. doi: 10.3390/ijms12074661.
- Thounaojam, M. C. *et al.* (2012) 'Sida rhomboidea.Roxb extract alleviates pathophysiological changes in experimental in vivo and in vitro models of high fat diet/fatty acid induced non-alcoholic steatohepatitis', *Experimental and Toxicologic Pathology*, 64(3), pp. 217–224. doi: 10.1016/j.etp.2010.08.009.
- Vijayakumar, K. *et al.* (2017) 'Hypolipidemic Effect of Psidium guajava Leaf Extract against Hepatotoxicity in Rats', *Pharmacognosy Magazine*, 13 (Suppl(62), pp. 179–188. doi: 10.4103/pm.pm.
- Wang, Y. *et al.* (2021) 'Apolipoprotein A4 regulates the immune response in carbon tetrachloride-induced chronic liver injury in mice', *International Immunopharmacology*, 90(157), p. 107222. doi: 10.1016/j.intimp.2020.107222.
- Van De Wier, B. *et al.* (2017) 'The potential of flavonoids in the treatment of non-

- alcoholic fatty liver disease', *Critical Reviews in Food Science and Nutrition*, 57(4), pp. 834–855. doi: 10.1080/10408398.2014.952399.
- Xia Cui, M. *et al.* (2017) 'Ciliary Neurotrophic Factor Analogue Aggravates CCl₄-induced Acute Hepatic Injury in Rats Ming-Xia', *Canadian Journal of Physiology and Pharmacology Ciliary*, 10, p. 2017. doi: DOI:10.1139/cjpp-2016-0564.
- Yan, C. *et al.* (2018) 'Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice', *Biomedicine and Pharmacotherapy*, 105(May), pp. 274–281. doi: 10.1016/j.biopha.2018.05.135.
- Yanai, H. *et al.* (2018) 'An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids', *Journal of Clinical Medicine Research*, 10(4), pp. 281–289. doi: 10.14740/jocmr3362w.
- Yeh, M. M. and Brunt, E. M. (2014) 'Pathological features of fatty liver disease', *Gastroenterology*, 147(4), pp. 754–764. doi: 10.1053/j.gastro.2014.07.056.
- Younossi, Z. M. *et al.* (2016) 'Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes', *Hepatology*, 64(1), pp. 73–84. doi: 10.1002/hep.28431.
- Yu, J. *et al.* (2016) 'The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background', *Gastroenterology Research and Practice*, 2016. doi: 10.1155/2016/2862173.
- Zeng, H. *et al.* (2015) 'Yhhu981, a novel compound, stimulates fatty acid oxidation via the activation of AMPK and ameliorates lipid metabolism disorder in ob / ob mice', *Nature Publishing Group*, pp. 343–352. doi: 10.1038/aps.2014.147.
- Zhang, G. *et al.* (2020) 'Carbon tetrachloride (CCl₄) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF)', pp. 1–13. doi: 10.21203/rs.3.rs-30324/v1.
- Zhong, F. *et al.* (2020) 'Rodent Models of Nonalcoholic Fatty Liver Disease', *Digestion*, 101(5), pp. 522–535. doi: 10.1159/000501851.
- Zhu, C. hua, Lei, Z. lin and Luo, Y. ping (2015) 'Studies on antioxidative activities of methanol extract from *Murraya paniculata*', *Food Science and Human Wellness*, 4(3), pp. 108–114. doi: 10.1016/j.fshw.2015.07.001.